Don Johns

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

Robert J. Heine, Luc F. Van Gaal, Don Johns et al. · Annals of Internal Medicine · 2005 · 794 citations

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Michael A. Nauck, Santiago Durán, D. Kim et al. · Diabetologia · 2006 · 439 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +8

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial

Anthony Barnett, Jude Burger, Don Johns et al. · Clinical Therapeutics · 2007 · 240 citations

Metabolic Syndrome, Diabetes Management, Insulin Management +8

Pioglitazone Reduces Atherogenic Index of Plasma in Patients with Type 2 Diabetes

Meng H. Tan, Don Johns, N. Bradly Glazer · Clinical Chemistry · 2004 · 207 citations · Full text

Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes

Imre Pávó, György Jermendy, Tamás Várkonyi et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 164 citations · Full text

Metabolic Syndrome, Insulin Sensitivity, Diabetes Management +13